Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.

Di Nisio, Marcello; van Es, Nick; Rotunno, Ludovica; Anzoletti, Nelson; Falcone, Leonardo; De Tursi, Michele; Natoli, Clara; Tinari, Nicola; Cavallo, Ilaria; Valeriani, Emanuele; Candeloro, Matteo; Guglielmi, Maria Domenica; Rutjes, Anne Wilhelmina Saskia; Porreca, Ettore (2019). Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. Journal of thrombosis and thrombolysis, 48(1), pp. 125-133. Springer 10.1007/s11239-019-01845-6

[img] Text
DiNisio JThrombThrombolysis 2019.pdf - Published Version
Restricted to registered users only until 28 March 2023.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img] Text
DiNisio JThrombThrombolysis 2019_postprint.pdf - Accepted Version
Restricted to registered users only until 28 March 2020.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, PROTECHT, CONKO, and ONKOTEV scores for the first 3-6 months and for 12 months, and re-assessed scores after 3-6 months to determine the influence of variations in patients' risk classification on performance. Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first or new line of chemotherapy. The primary outcome was symptomatic or incidental VTE. A total of 776 patients were included of whom 540 (70%) had distant metastases. The time-dependent c-statistics of Khorana, PROTECHT, CONKO, and ONKOTEV scores at 6 months were 0.61 (95% CI 0.56 to 0.66), 0.61 (95% CI 0.55 to 0.66), 0.60 (95% CI 0.54 to 0.66), and 0.59 (0.52 to 0.66), respectively, with a tendency to decrease during follow-up. None of the scores discriminated between high and low risk patients at the conventional 3-point positivity threshold. The use of a 2-point positivity threshold improved performance of all scores and captured a higher proportion of VTE. The accuracy of risk scores re-assessed at 3-6 months was modest. The Khorana, PROTECHT, CONKO, and ONKOTEV scores are not sufficiently accurate when used at a conventional threshold of 3 points. Performance improves at positivity threshold of 2 points, as evaluated in recent randomized studies on VTE prophylaxis. Score accuracy tends to decrease over time suggesting the need of periodic re-evaluation to estimate possible variation of risk.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)

UniBE Contributor:

Rutjes, Anne

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0929-5305

Publisher:

Springer

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

02 Apr 2019 12:51

Last Modified:

05 Dec 2019 16:24

Publisher DOI:

10.1007/s11239-019-01845-6

PubMed ID:

30919253

Uncontrolled Keywords:

Biomarkers Neoplasms Predictive value of tests Venous thromboembolism Venous thrombosis

BORIS DOI:

10.7892/boris.129880

URI:

https://boris.unibe.ch/id/eprint/129880

Actions (login required)

Edit item Edit item
Provide Feedback